People with rheumatoid arthritis who were treated with the biologics tofacitinib (Xeljanz) or tocilizumab (Actemra) had a more than two-fold risk of lower gastrointestinal tract (GI) perforation compared to those treated with TNF inhibitors, a new study shows. GI perforation is a rare but serious side effect that is most typically seen in RA patients on NSAIDs. The researchers concluded that this risk “is clearly only one consideration in evaluating the overall risk-benefit profile of choosing a specific therapy.”

Click here for more.